One of Switzerland's leading chemical and pharmaceutical companies, Sandoz, is to demerge in order to focus on its pharmaceutical and nutrition business. The restructuring involves the separating-off of the chemicals division into an independent business.
Sandoz said that the new status will allow the chemicals business to invest in line with its own priorities. The company will be free to organize its development optimally and its management will be better able to seize market opportunities.
The actual form of the demerger has not yet been decided but a variety of scenarios are understood to be under consideration, including the sale of the chemical business. Marc Moret, Sandoz' chairman, has said that he does not want to see the business broken up, and that he would like to see a deal completed in the second half of the year. The establishment of an independent quoted company is the preferred solution.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze